Corcept Therapeutics is trading 5.26% higher at $90.38 on October 26 after positive Phase 2 BELLA Part A results. - Among 95 patients with platinum-resistant ovarian cancer, the Lifyorli combination showed 7.2-month median progression-free survival and a 59% objective response rate. - The announcement was cited as a premarket rebound driver; modest market gains do not fully explain the rise. - Shares closed at $85.86 on October 23, down 20.13%, after Genmab reported positive Phase 3 cancer-trial results, raising competitive concerns.